Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
Year: 2018
Type: article
Abstract: Background: In patients with metastatic EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), resistance to EGFR tyrosine kinase inhibitors (TKIs) arises from the T790M EGFR mutation in over half of cases; up-regulation of “bypass track” activity in non-EGFR signaling pathways is observed in other cases. Up-regulation of expression of the AXL tyrosine kinase has been observed in EGFRm NSCLC patients experiencing disease progression on erlotinib, and xenograft studies have supported the role of AXL inhibition in combination with EGFR TKI treatment in overcoming such resistance.
Source: Annals of Oncology
Authors: D. Planchard, P.A. Janne, H.A. Yu, D. Moro-Sibilot, T. Goldberg, X. Gu, J. Li, J. McGill, C. Yu, E. Slosberg
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2895962368